3billion (394800.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
3billion financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 5.77 bn KRW | 11.71 bn KRW |
| Gross profit | 4.10 bn KRW | 11.71 bn KRW |
| Operating income | -7.42 bn KRW | -5.89 bn KRW |
| EBIT | -6.55 bn KRW | -5.21 bn KRW |
| Net income | -6.57 bn KRW | -5.41 bn KRW |
| Diluted EPS – continuing operations | -207.41 KRW | -170.59 KRW |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About 3billion
3billion, Inc. develops technology for rare disease drug discovery using bioinformatics and machine learning technology. The company focuses on developing methods for novel drug target discovery, drug candidate generation, and safety assessment. It offers genetic and biomolecular testing services related to the analysis of biologic samples of patients suspected to have rare genetic disorders, as well as provides various affiliated services to customers. The company was founded in 2016 and is based in Seoul, South Korea.
More stocks
- Yg Plus Inc (037270.KS)
- BINEX Co. Ltd (053030.KQ)
- Ferro S.A. (FRO.WA)
- Orvana Minerals Corp. (ORV.TO)
- Namuga Co. Ltd (190510.KQ)
- E-Life Mall Corp (6281.TW)
- Croghan Bancshares Inc (CHBH)
- KANGWON Co. Ltd (114190.KQ)
- Riber S.A (ALRIB.PA)
- Universal Token (UTKN)
- Kunyue Development Co Ltd (5206.TWO)
- enGene Therapeutics Inc. (ENGN)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.